- Home
- FTHM vs LTRN Comparison
FTHM vs LTRN Comparison
Compare FTHM & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | LTRN |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 27.6M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FTHM | LTRN |
|---|---|---|
| Price | $0.58 | $1.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 86.5K | ★ 143.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.40 | $1.11 |
| 52 Week High | $3.37 | $4.70 |
Technical Indicators
Market Signals| Indicator | FTHM | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 21.29 |
| Support Level | $0.57 | $1.11 |
| Resistance Level | $0.71 | $3.01 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 13.33 | 5.80 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.